2018-04-23 16:00Financial Performance - The company's operating revenue for Q1 2018 was CNY 2,369,123,463.71, representing an increase of 11.43% compared to CNY 2,126,032,700.53 in the same period last year[4] - Net profit attributable to shareholders for Q1 2018 was CNY 347,363,915.08, reflecting a growth of 26.31% from CNY 275,011,096.84 year-on-year[4] - The net profit after deducting non-recurring gains and losses was CNY 284,962,982.12, which is a 19.56% increase from CNY 238,343,079.15 in the previous year[4] - The basic earnings per share for Q1 2018 was CNY 0.63, up 23.53% from CNY 0.51 in the same period last year[4] - Revenue for the first quarter was RMB 531 million, a year-on-year decrease of 6.99%[16] Assets and Liabilities - The total assets at the end of the reporting period were CNY 16,156,947,209.89, an increase of 1.63% from CNY 15,897,730,717.63 at the end of the previous year[5] - The net assets attributable to shareholders at the end of Q1 2018 were CNY 11,079,097,592.61, which is a 2.84% increase from CNY 10,772,739,768.63 at the end of the previous year[5] - Short-term borrowings increased to RMB 150 million, reflecting an increase in subsidiary borrowings[14] Cash Flow - The net cash flow from operating activities decreased by 19.24% to CNY 208,115,855.40 from CNY 257,702,732.97 in the same period last year[4] - Cash flow from investment activities saw a drastic decline of 99.95% to RMB 371,064.09 due to last year's equity transfer guarantees[18] - Cash flow from financing activities increased by 1,043.27% to RMB 188.82 million, primarily due to increased borrowings from subsidiaries[18] Revenue Breakdown - The revenue from Western medicine products reached RMB 1.096 billion, a year-on-year growth of 16.07%[15] - Diagnostic reagents and equipment generated revenue of RMB 154 million, a year-on-year increase of 19.09%[16] - Key formulation products showed varied performance: sales of Shenqi Fuzheng Injection decreased by 24.74% to RMB 298 million, while antiviral granules increased by 36.91% to RMB 181 million[16] - Sales of Aprazole enteric-coated tablets grew by 44.61% to RMB 140 million, and sales of Rebeprazole increased by 66.63% to RMB 73.21 million[16] - Revenue from active pharmaceutical ingredients (APIs) showed significant growth: Milbemycin Oxime increased by 239.93% to RMB 41.39 million, and Simvastatin grew by 146.70% to RMB 36.74 million[17] Shareholder Information - The total number of common shareholders at the end of the reporting period is 40,508, including 40,499 A-share shareholders and 9 H-share shareholders[11] - The top 10 shareholders hold a combined 62.68% of the shares, with Hong Kong Central Clearing Limited holding 34.20% and Health元药业集团股份有限公司 holding 23.68%[11] Non-Recurring Gains and Losses - The company reported non-recurring gains of CNY 62,400,932.96 for the period, primarily from government subsidies and other income[8] - The company reported a significant increase in government subsidies, with operating other income rising by 135.05% to RMB 58.50 million[15] - The asset impairment loss increased by 62.08% to RMB 12.75 million, primarily due to an increase in receivables[15] Corporate Actions and Plans - The company proposed a cash dividend of RMB 20.00 per 10 shares and a capital reserve conversion of 3 shares for every 10 shares held, totaling RMB 1.11 billion[20] - The company approved a capital increase for its subsidiary Livzon Biologics, amounting to RMB 306 million and RMB 294 million from respective shareholders[20] - The company is focusing on internationalizing its monoclonal antibody business and attracting talent through equity structure adjustments[20] - The company completed the equity change registration for Lijun Biopharmaceuticals, maintaining a 51% stake for the company and 49% for Health元[21] - A total of 28,431 restricted shares were repurchased and canceled due to non-compliance with incentive conditions, while 4,038,407 shares were unlocked for 413 eligible participants[21] Risk Management - The company has established a foreign exchange risk management policy to mitigate market, operational, and legal risks associated with derivative investments[28] - The company utilized foreign exchange forward contracts to hedge against currency risk, with a fair value change gain of 1.93 million RMB during the reporting period[28] - The company emphasizes a cautious and prudent approach to derivative trading, avoiding speculative transactions[28] Compliance and Governance - The company reported no violations regarding external guarantees during the reporting period[30] - There were no non-operating fund occupations by controlling shareholders or related parties during the reporting period[31] - The company’s independent directors support the derivative investment strategy, confirming adherence to legal and regulatory requirements[28] Future Outlook - The company does not anticipate significant changes in net profit for the first half of 2018 compared to the previous year[24]